Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis

Table 1 Cohort characteristics, n = 631

Characteristics
Age (years) at diagnosis (median, IQR)	Median	IQR
	5.6	3.6–9.3
	N	%
Gender
Male	177	28.1
Female	454	71.9
Ethnicity
Hispanic	95	15.1
Race
Caucasian	519	82.3
African-American	82	13
JDM Category
Amyopathic	9	1.4
Probable	490	77.7
Definite	48	7.6
Missing	84	13.3
History of Calcinosis	84	13.3
History of biologic use	242	38.4
IVIG	225	35.7
Rituximab	26	4.1
Anti-TNF^a	35	5.6
Certolizumab	0	0
Etanercept	22	3.5
Golimumab	1	0.2
Adalimumab	7	1.1
Infliximab	13	2
Abatacept	3	0.48
Anti-IL1^b	2	0.32
High glucocorticoid exposure^c (n = 572)	316	50

^aComposite which includes etanercept, infliximab, adalimumab, certolizumab, golimumab
^bComposite which includes anakinra, canakinumab, rilonacept
^cComposite defined as history of IV pulse steroids and daily corticosteroids for ≥ 1 month

ISSN: 1546-0096